PPARG and liver cancer: In this study, we showed that PPARγ agonists (15d-PGJ2 or rosiglitazone) effectively inhibited stem cell-like properties in human liver cancer cells, and that NADPH oxidase-2 (NOX2)-induced reactive oxygen species (ROS) generation functioned as a key downstream event.